Olorofim
- Generic Name
- Olorofim
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H27FN6O2
- CAS Number
- 1928707-56-5
- Unique Ingredient Identifier
- T34SH2H9HI
- Background
Olorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
Review of the novel antifungal drug olorofim
Article discusses antifungal resistance in human pathogens and implications of dual use in medicine and agriculture, highlighting studies on azole resistance in Aspergillus fumigatus and invasive aspergillosis outcomes. It references global guidelines for diagnosis and management of fungal infections and emerging antifungal agents.
Seaport Therapeutics Secures $225M for New Kind of Depression Drug
Seaport Therapeutics raised $225 million to advance its lead drug candidate for depression, leveraging its Glyph technology platform. The company aims to advance its pipeline through clinical milestones and further develop its Glyph technology.
F2G raises $100M to bring antifungal drug back to FDA
F2G raises $100M to complete Phase 3 testing of olorofim, a novel antifungal for invasive aspergillosis, after FDA rejection. AMR Action Fund and ICG co-led the funding, joined by eight other investors. F2G aims to address FDA concerns and prepare for U.S. launch.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath